INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 186 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $633,000 | +146.3% | 27,435 | +163.7% | 0.00% | – |
| Q4 2020 | $257,000 | -91.7% | 10,404 | -84.0% | 0.00% | -100.0% |
| Q2 2020 | $3,106,000 | -54.7% | 64,829 | -40.4% | 0.00% | -63.6% |
| Q1 2020 | $6,851,000 | -55.9% | 108,821 | -21.3% | 0.01% | -45.0% |
| Q4 2019 | $15,522,000 | +116.7% | 138,264 | +13.6% | 0.02% | +100.0% |
| Q3 2019 | $7,164,000 | +1.9% | 121,744 | +5.5% | 0.01% | 0.0% |
| Q2 2019 | $7,033,000 | -18.8% | 115,349 | +14.6% | 0.01% | -23.1% |
| Q1 2019 | $8,660,000 | -3.2% | 100,630 | +13.4% | 0.01% | -18.8% |
| Q4 2018 | $8,946,000 | -9.5% | 88,761 | +13.5% | 0.02% | +6.7% |
| Q3 2018 | $9,883,000 | +50.1% | 78,211 | -0.3% | 0.02% | +36.4% |
| Q2 2018 | $6,585,000 | +37.0% | 78,476 | +0.4% | 0.01% | +22.2% |
| Q1 2018 | $4,808,000 | +141.5% | 78,152 | +129.4% | 0.01% | +125.0% |
| Q4 2017 | $1,991,000 | +805.0% | 34,073 | +1648.2% | 0.00% | +300.0% |
| Q1 2017 | $220,000 | – | 1,949 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |